Weight Loss From Combination Anti-Obesity Medication Regimens Can Approach that Achieved From Bariatric Surgery.
Weight Loss From Combination Anti-Obesity Medication Regimens Can Approach that Achieved From Bariatric Surgery.
复制标题
DOI：
10.1210/jcemcr/luac038
复制
发表时间：
2023-01
期刊：
影响因子：
--
通讯作者：
Bomberg, Eric M
中科院分区：
文献类型：
--
作者：
Patel, Priya N;Fox, Claudia K;Bensignor, Megan O;Bomberg, Eric M
肥胖是一种多因素慢性疾病，治疗仍然具有挑战性。虽然基础治疗是改变生活方式，但添加抗肥胖药物会导致更大的体重减轻。在使用单一抗肥胖药物的单药治疗导致体重稳定或仅适度减轻的情况下，联合方案可能非常有效，特别是包括胰高血糖素样肽-1受体激动剂的那些。我们报告的情况下，23岁的男性最初提出的体重指数为84.3公斤/平方米。 除了生活方式改变治疗外，他还开始服用芬特明、托吡酯和二甲双胍，仅在1年后体重稳定。随后，添加Semaglutide（一种胰高血糖素样肽-1受体激动剂），沿着低热量饮食，导致总体重减轻32.5%，接近代谢/减肥手术后可达到的体重。该病例强调了包括胰高血糖素样肽-1受体激动剂在内的联合抗肥胖药物治疗方案的潜在益处，因为此类治疗方案可通过同时靶向多种进食行为途径提供协同效应。需要进一步的研究来评估联合抗肥胖药物治疗方案的疗效，特别是在那些对单一疗法达到次优反应的患者中。
Obesity is a multifactorial chronic disease for which treatment remains challenging. While the cornerstone treatment is lifestyle modification, the addition of anti-obesity medications leads to greater weight reduction. In cases where monotherapy with a single anti-obesity medication results in either weight stabilization or only modest weight reduction, combination regimens can be highly effective, especially those including glucagon-like peptide-1 receptor agonists. We report the case of a 23-year-old male initially presenting with a body mass index of 84.3 kg/m2. In addition to lifestyle modification therapy, he was started on phentermine, topiramate, and metformin, which only resulted in weight stabilization after 1 year. Subsequently, semaglutide (a glucagon-like peptide-1 receptor agonist) was added, along with a lower calorie diet, which resulted in a 32.5% total body weight reduction, approximating that which can be achieved following metabolic/bariatric surgery. This case highlights the potential benefit of combination anti-obesity medication regimens including glucagon-like peptide-1 receptor agonists, as such regimens may provide a synergistic effect by targeting multiple eating behavior pathways simultaneously. Further studies are needed to evaluate the efficacy of combination anti-obesity medication regimens, especially among those achieving suboptimal response to monotherapies.